Vosevi (Sofosbuvir/Velpatas/Voxilaprev) Patent Expiration, LOE Window & CMS Spending

Vosevi (Sofosbuvir/Velpatas/Voxilaprev) by Gilead Sciences: FDA Orange Book core substance LOE 2034-07-17 (last listed 2037-12-01), 0 AB generics, $84.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN209195 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-07-17
Last Listed Patent or Exclusivity Date2037-12-01
Orange Book Patents (*PED Extensions)32 patents (14 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$84.5M
2024 Medicare Part D Spend$45.2M
2024 Medicaid Spend$39.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.